ERBB2 and neoplasm: Still, despite the widespread use and clinical validation of this dual HER2 blockade combination, the effect in the anti-tumor immune function induced by the addition of pertuzumab has been only briefly addressed in human experimental models, such as 2D ADCC assays, and yielded conflicting results (65, 66, 92, 93, 130).